Pharmaceutical Market Europe • March 2024 • 34
APPOINTMENTS
AbbVie
Robert Michael
AbbVie has appointed Robert Michael as chief executive officer. Michael has over 30 years of experience, including from leadership roles across multiple businesses such as pharmaceuticals, diagnostics, diabetes care and nutrition. Michael, who has also been appointed as a member of AbbVie's board of directors, originally joined the company over a decade ago as vice president, financial planning and analysis. He has since held roles of increasing responsibility, most recently serving as vice chairman and president, and then as president and chief operating officer. Prior to joining AbbVie, Michael worked at Abbott for nearly two decades in a variety of positions, first as a member of the company's financial development programme and finally as division controller, nutrition supply chain and division controller, molecular diagnostics.
Maxion Therapeutics
Arndt Schottelius
Maxion Therapeutics has appointed Arndt Schottelius as chief executive officer. Schottelius has over two decades of experience in the pharmaceutical industry. He most recently served as chief scientific officer at Affimed. Prior to this, he served as executive vice president and head of research and development at Kymab, and has held positions at Genentech and Bayer.
OneChain Immunotherapeutics
Stefanos Theoharis
OneChain Immunotherapeutics has appointed Stefanos Theoharis as chief executive officer. Theoharis has over two decades of experience in several senior positions. Most recently, he has been serving as managing director at Venture Advanced Therapies as well as venture partner and sector scoping committee member at Deep Science Ventures. Prior to this, he worked at Bone Therapeutics.
Abdera Therapeutics
Philippe Bishop
Abdera Therapeutics has appointed Philippe Bishop as chief medical officer. Bishop has over two decades of experience and has held multiple senior positions. He most recently served as chief medical officer at Atreca. Prior to this, he was chief medical officer at Clover Biopharmaceuticals and also worked at companies including Gilead Sciences, Genentech and Johnson & Johnson.
Enhanc3D Genomics
Daniel Turner
Enhanc3D Genomics has appointed Daniel Turner as chief scientific officer. Turner has over 20 years of senior leadership experience. For over a decade, he served in multiple positions at Oxford Nanopore Technologies, most recently as senior vice president, applications. Prior to this, Turner served as head of sequencing, technology development at the Wellcome Trust Sanger Institute.
Gilead Sciences
Ted Love
Gilead Sciences has appointed Ted Love to its board of directors. Love holds over two decades of broad management experience. He is chair of the board of directors of the Biotechnology Innovation Organization and serves on the boards of Royalty Pharma and Structure Therapeutics. Previously, he was president and chief executive officer of Global Blood Therapeutics.
Poolbeg Pharma
Cathal Friel
Poolberg Pharma has appointed Cathal Friel as executive chairman. Friel brings a wealth of experience in mergers and acquisitions, and investment banking to his new position. He has been serving as chairman and co-founder of both Poolbeg and hVIVO. Friel also serves as founder and managing director of Raglan Capital, and is also director at IMUTEX.
Zymeworks
Alessandra Cesano
Zymeworks has appointed Alessandra Cesano to its board of directors. Cesano has over two decades of experience in drug development, diagnostics and cancer. She currently serves as chief medical officer at ESSA Pharmaceuticals, having held the same position at NanoString Technologies. Earlier in her career, Cesano held a variety of roles at Cleave Biosciences, Nodality, Biogen and Amgen.
Abdera Therapeutics
Eric Dobmeier
Abdera Therapeutics has appointed Eric Dobmeier as a member of its board of directors. Dobmeier holds over two decades of experience in the biotechnology industry. Most recently, he served as president and chief executive officer of Chinook Therapeutics. Prior to this, he was president and chief executive officer of Silverback Therapeutics and held successive leadership positions at Seagen.